Unknown PHASE4 INTERVENTIONAL NCT01002508

Influenza Vaccination in Patients With Scleroderma

Safety and Efficacy of Vaccination Against Influenza in Patients With Scleroderma

Sponsor: Tel-Aviv Sourasky Medical Center

Conditions Influenza Vaccine in Scleroderma

Updated 6 times since 2017 Last updated: Oct 26, 2009 Started: Nov 30, 2009 Primary completion: Mar 31, 2010 Completion: Mar 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Influenza Vaccine in Scleroderma, this trial is ongoing. The trial is conducted by Tel-Aviv Sourasky Medical Center and has accumulated 6 data snapshots since 2009. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE4
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE4
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE4

First recorded

Nov 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tel-Aviv Sourasky Medical Center

Data source: Tel-Aviv Sourasky Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tel Aviv, Israel